Targeted therapies in CLL – the dawn of a new era

Sponsored by AbbVie Pty Ltd

Chronic lymphocytic leukaemia (CLL) has traditionally been one of the most challenging leukaemias for clinicians to manage.1 Treatment options have been evolving for decades, and never faster than right now.2 To reflect upon the age of chemotherapy to chemo-immunotherapy and now targeted therapy, the limbic sat down with Professor John Seymour, Co-Director of the Division of Cancer Medicine, and ...

Already a member?

Login to keep reading.

© 2022 the limbic